Number of items: 2.
Koeberle, D; Dufour, J-F; Demeter, G; Li, Q; Ribi, K; Samaras, P; Saletti, P; Roth, A D; Horber, D; Buehlmann, M; Wagner, A D; Montemurro, M; Lakatos, G; Feilchenfeldt, J; Peck-Radosavljevic, M; Rauch, D; Tschanz, B; Bodoky, G; Swiss Group for Clinical Cancer Research (SAKK) (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology, 27(5):856-861.
Bernhard, J; Dietrich, D; Scheithauer, W; Gerber, D; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B C; Köhne, C H; Mingrone, W; Stemmer, S M; Tàmas, K; Kornek, G V; Koeberle, D; Herrmann, R (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology, 26(22):3695-3701.
This list was generated on Thu Jun 20 04:03:11 2019 CEST.
